Koers ASKA Pharmaceutical Co., Ltd. Japan Exchange
Aandelen
4514
JP3541200006
Farmaceutische producten
Omzet 2024 * | 63,28 mld. 406 mln. 379 mln. | Omzet 2025 * | 64,65 mld. 415 mln. 387 mln. | Marktkapitalisatie | 64,99 mld. 417 mln. 389 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 6,47 mld. 41,47 mln. 38,7 mln. | Nettowinst (verlies) 2025 * | 4,89 mld. 31,39 mln. 29,29 mln. | EV/omzet 2024 * | 0,77 x |
Nettoliquiditeiten 2024 * | 16,35 mld. 105 mln. 97,86 mln. | Nettoliquiditeiten 2025 * | 20,83 mld. 134 mln. 125 mln. | EV/omzet 2025 * | 0,68 x |
K/w-verhouding 2024 * |
10
x | K/w-verhouding 2025 * |
13,3
x | Werknemers | 747 |
Dividendrendement 2024 * |
1,74% | Dividendrendement 2025 * |
2,09% | Vrij verhandelbaar | 0% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
President | 72 | 01-04-21 | |
Kiyohiko Tamura
ADM | Chief Administrative Officer | - | - |
Kunihiro Gunji
CMP | Compliance Officer | - | 01-04-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
President | 72 | 01-04-21 | |
Atsushi Maruo
BRD | Director/Board Member | 65 | 01-04-21 |
Director/Board Member | 75 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,25% | 704 mld. | |
+28,59% | 577 mld. | |
-3,55% | 348 mld. | |
+18,16% | 327 mld. | |
+4,36% | 288 mld. | |
+14,81% | 234 mld. | |
+4,93% | 198 mld. | |
-9,78% | 194 mld. | |
-3,69% | 147 mld. |